Halozyme Therapeutics, Inc. (HALO)

Nasdaq · Healthcare · Biotechnology
$91.35-1.82%As of 2026-11-22 · USD
Last session low $90.79Last session high $93.55
52-week low $61.2352-week high $134.00
Market cap
$10.41B
Sector
Healthcare
P/E (TTM)
22.8x

Market data and research context for informational purposes. Not investment advice.

Technical indicators

Indicators from the 2026-11-20 daily bar; Bollinger %B and the average rows compare the latest price with those values. Prices in USD.

IndicatorValueReading
RSI (14)21.1In the oversold range (below 30)
MACD (12, 26, 9)-6.69Below its signal line (-4.09); histogram -2.60
Bollinger %B (20, 2)16%Inside the bands (81.67 to 142.91)
SMA 20112.29Price is 18.6% below
SMA 50113.24Price is 19.3% below
SMA 20085.91Price is 6.3% above
ATR (20)4.31% of priceAverage true range per day
52-week position41%In the middle of the 61.23 to 134.00 range

About Halozyme Therapeutics, Inc.

Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally.

Insider filings, 90 daysNo purchases and 8 sales (about $15.7M).
Latest fiscal yearEnded 2025-12-31: revenue of $1.40B and an operating margin of 57.5%.

More in Biotechnology